Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FX006 vs TCA IR in OA Knee with T2DM
NCT02762370Phase 2Completed
- Sponsor
- Pacira BioSciences
- Start
- Apr 2016
- Primary completion
- Oct 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of triamcinolone acetonide in osteoarthritis (OA) (2 arms), sponsored by Pacira BioSciences. Primary endpoint: Change From Baseline for Average Blood Glucose at 72 hours. Started Apr 2016; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02762370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762370.